Patent intelligence · EP
EP 1296670
THERAPEUTISCHE KOMBINATIONEN VON FETTSÄUREN
THERAPEUTISCHE KOMBINATIONEN VON FETTSÄUREN
Patent details — EP 1296670
- Jurisdiction
- EP
- Status
- expired
- Grant date
- Apr 2, 2003
- Expiration
- Mar 28, 2023
- Applicant
- LAXDALE LTD [GB]
- CPC classes
- A61K 31/ 20 A I, A61K 31/ 202 A I, A61K/3120, A61K/31202
Quick answer
EP 1296670 (THERAPEUTISCHE KOMBINATIONEN VON FETTSÄUREN) is held by LAXDALE LTD [GB]. Status: expired. Granted Apr 2, 2003. Expires Mar 28, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- LAXDALE LTD [GB]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 20 A I, A61K 31/ 202 A I, A61K/3120, A61K/31202, A61K31/202, A61P 1/ 04 A I
More from LAXDALE LTD [GB]
Related pharmaceutical patents in our USPTO index.
-
CA 2754902
COMPOSES D'ACIDE GRAS ESSENTIEL
granted -
IL 159038
USE OF COENZYME Q AND EICOSAPENTAENOIC ACID (EPA) FOR THE PREPARATION OF MEDICAMENTS
granted -
DK 1007053
Behandling af smerte
granted -
CA 2591889
TRAITEMENT DE LA DEPRESSION MELANCOLIQUE SEVERE A L'AIDE D'EPA
granted -
SI 1148873
HIGHLY PURIFIED ETHYL EPA AND OTHER EPA DERIVATIVES FOR NEUROLOGICAL DISORDERS
expired -
IS 7744
Eikósapentanó sýra (EPA) til notkunar við meðhöndlun á lystarstoli (AN) og matgræðgi
expired -
CA 2506727
TRAITEMENT DE LA MALADIE DE HUNTINGTON AU MOYEN D'ACIDE EICOSAPENTAENOIQUE
expired -
EP 1392276
VERSTÄRKTE WIRKUNG MEHRFACH UNGESÄTTIGTER FETTSÄUREN
expired
Frequently asked questions
What is US patent 1296670?
EP 1296670 (THERAPEUTISCHE KOMBINATIONEN VON FETTSÄUREN) is held by LAXDALE LTD [GB]. Status: expired. Granted Apr 2, 2003. Expires Mar 28, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 1296670?
LAXDALE LTD [GB] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 11 pharmaceutical patents for this assignee.
When does EP 1296670 expire?
Our index shows an expiration date of Mar 28, 2023 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.